BPC-157 vs TB-500: A Research Comparison
Quick Summary
BPC-157 and TB-500 are the two most extensively studied tissue-repair research peptides in published literature. They operate through distinct mechanism families — BPC-157 acts through VEGFR2 / FAK-paxillin / NO signaling; TB-500 acts through G-actin sequestration and cell-migration dynamics. Researchers compare and combine them to characterize complementary approaches to tissue-repair endpoints.
BPC-157
Overview BPC-157 (Body Protection Compound-157, Bepecin, PL 14736) is a synthetic pentadecapeptide composed of 15 amino acids (GEPPPGKPADDAGLV), derived from a partial sequence of a larger Body Protection Compound protein naturally found in human gastric juice.[1][2] Originally isolated by Dr....
TB-500
Overview TB-500 (also known as Fequesetide) is a synthetic heptapeptide corresponding to the N-acetylated amino acid sequence 17–23 of the naturally occurring protein Thymosin Beta-4 (Tβ4). Its sequence is Ac-LKKTETQ.[1][2] The parent molecule, Thymosin Beta-4, is a ubiquitous 43-amino acid...
BPC-157 and TB-500 are the two most-cited tissue-repair research peptides in modern peptide-research literature. Both are widely used in preclinical and ex-vivo research models targeting tendon, ligament, dermal, gastric, and cardiac endpoints. Despite the overlapping research-application landscape, the two molecules represent fundamentally different mechanism families, which is why they are so often paired in research stacks.
BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a gastric-juice protein — the Body Protection Compound (BPC). It is one of the few peptides reported to maintain stability in gastric juice for over 24 hours, enabling oral-route research designs in addition to standard parenteral and topical formats.
TB-500 is the active C-terminal fragment of Thymosin β4 (Tβ4), the principal G-actin-sequestering molecule in cells. The fragment retains the actin-binding and cell-migration activity of the parent protein in a smaller, more synthetically tractable peptide that is widely used as a research tool compound. Tβ4 has its own substantial Phase 2 cardiac-research literature; TB-500 inherits much of that mechanism profile.
This page contrasts the two compounds across structure, mechanism family, primary research applications, common research stack pairings, and the SKU sizes Pure U.S. Peptides supplies for in-vitro research.
Side-by-Side: BPC-157 vs TB-500
| Property | BPC-157 | TB-500 |
|---|---|---|
| Compound class | Synthetic pentadecapeptide (gastric-juice derivative) | Thymosin β4 active fragment (synthetic peptide) |
| Sequence length | 15 amino acids (GEPPPGKPADDAGLV) | Active C-terminal fragment of Tβ4 (~17 aa region) |
| Reported half-life | <30 min (IV/IM in research) | Short plasma half-life; metabolized rapidly in research models |
| Primary mechanism family | VEGFR2 / Akt / eNOS, FAK-paxillin, NO bidirectional modulation | G-actin sequestration, cell-migration dynamics, anti-fibrotic NF-κB modulation |
| Primary research applications | GI-tract repair, tendon/ligament, peripheral nerve, VEGFR2-driven angiogenesis | Dermal cell-migration assays, corneal repair, cardiac-tissue research, anti-fibrotic models, hair-follicle research |
| Common research stack pairings | TB-500, GHK-Cu, KPV (in GLOW / KLOW blends) | BPC-157, GHK-Cu, KPV (in GLOW / KLOW blends) |
| SKU sizes available | 5 mg, 10 mg vials | 2 mg, 5 mg, 10 mg vials |
| Indicative price range | $$ | $$ |
How the Two Peptides Differ Mechanistically
BPC-157 engages multiple converging signaling pathways. The most-characterized layer is activation and internalization of VEGFR2 on endothelial cells, with downstream Akt phosphorylation, eNOS activation, and nitric-oxide production supporting angiogenesis in research models.[1][2] A second layer is engagement of the FAK-paxillin pathway in tendon fibroblasts, supporting cell migration, adhesion, and cytoskeletal organization during connective-tissue research endpoints.[3] A third layer is JAK-2 activation linked to upregulation of the growth-hormone receptor on tendon fibroblasts. A fourth, distinctive layer is bidirectional modulation of the nitric-oxide system — BPC-157 is reported to counteract both NOS inhibition and NOS substrate excess in research models, behaving as a homeostatic buffer rather than a strict agonist or antagonist.[4]
TB-500 is built around a single core mechanism: sequestration of monomeric G-actin via the actin-binding domain inherited from Thymosin β4. By buffering the intracellular G-actin pool, TB-500 influences actin polymerization dynamics during cell migration, lamellipodia formation, and tissue-repair processes.[5][6] Downstream effects in published research include accelerated cell migration in dermal and corneal models, anti-fibrotic signaling via reduced TGF-β downstream activity, and modulation of the NF-κB pathway in inflammation-research models.[7] In endothelial-cell research, TB-500 supports tube formation through actin-cytoskeleton mechanisms — a different angiogenesis-research route than BPC-157’s direct VEGFR2 agonism.
The mechanistic point of difference is therefore architectural. BPC-157 acts as a multi-pathway receptor and signaling agonist with a defined VEGFR2 / FAK / eNOS axis. TB-500 acts on the cytoskeleton via actin-binding and produces tissue-repair effects via cell-migration dynamics. The two mechanism families are largely orthogonal, which is the basis for their frequent pairing in research stacks (most notably the GLOW and KLOW research blends).
Research Applications Compared
BPC-157 is most-cited in gastric-tract research (the original research context, with reported endpoints across gastric, intestinal, and colonic models in published preclinical literature), tendon and ligament research (FAK-paxillin and growth-hormone-receptor-upregulation endpoints in fibroblast research), peripheral-nerve research, and angiogenesis assays driven by VEGFR2 activation. The reported gastric-juice stability is a distinguishing research feature that permits oral-route designs.
TB-500 is most-cited in dermal-research models (cell-migration assays, wound-closure research), corneal-research (Tβ4 has a substantial corneal literature inherited by TB-500), cardiac-tissue research (Tβ4 has been studied in cardiac-repair Phase 2 research, with TB-500 used as a tool compound in preclinical extensions), anti-fibrotic research models, and hair-follicle research designs. The actin-binding mechanism makes TB-500 the standard research tool when cell-migration endpoints dominate the design.
The two compounds are extensively studied together in research stacks combining both mechanism families. The most-cited combinations are the GLOW blend (GHK-Cu + BPC-157 + TB-500) and the KLOW blend (KPV + GHK-Cu + BPC-157 + TB-500), both of which layer the BPC-157 VEGFR2 / FAK background with the TB-500 actin-cytoskeleton mechanism in a single research vial.
Choosing Between Them
When researchers choose BPC-157
BPC-157 is the preferred research compound when the design centers on receptor- or pathway-level mechanisms — VEGFR2 activation, FAK-paxillin signaling in fibroblasts, eNOS-mediated angiogenesis, gastric-tract or tendon-repair endpoints, or peripheral-nerve research. Its gastric-juice stability also makes it the standard tool compound when an oral-route research design is required.
When researchers choose TB-500
TB-500 is the preferred research compound when the experimental design centers on cell-migration endpoints, actin-cytoskeleton dynamics, anti-fibrotic signaling, corneal- or cardiac-tissue research, or hair-follicle research. It is also the standard tool compound for Thymosin β4 fragment research where a smaller, more synthetically tractable peptide is preferred over the full-length parent.
Detailed Research Dimensions
| Dimension | BPC-157 | TB-500 |
|---|---|---|
| Origin | Gastric juice-derived pentadecapeptide (15 amino acids) | Thymosin beta-4 fragment (~17 aa active region) |
| Primary Mechanism | VEGFR2 / Akt-eNOS, FAK-paxillin pathway, NO bidirectional modulation | G-actin sequestration, cell migration promotion, NF-κB modulation |
| Primary Research Focus | Gastrointestinal repair, tendon/ligament research, peripheral nerve research | Cardiac tissue research, corneal repair, dermal cell-migration assays, anti-fibrotic models |
| Administration Routes Studied | Oral (unique for peptides), IP, topical, IM, SC | Subcutaneous, IP, topical |
| Stability | Highly stable in gastric juice (unique characteristic) | Standard peptide stability; requires reconstitution |
| Key Signaling Pathways | JAK-2 / GHR upregulation, VEGFR2, eNOS/NO, FAK | Actin cytoskeleton, NF-κB suppression, Akt-related migration signaling |
| Angiogenesis | Promotes via VEGFR2 activation | Promotes via endothelial cell migration and tube formation |
| Anti-inflammatory | COX-2 pathway modulation, prostaglandin system | NF-κB inhibition, cytokine downregulation |
| Neuroprotective Effects | Dopaminergic system protection, peripheral nerve repair | Oligodendrocyte differentiation, axonal regrowth |
| Research Stage | Extensive preclinical (800+ publications) | Extensive preclinical (1000+ publications), Tβ4 Phase II cardiac research |
Chemical Properties Comparison
| Property | BPC-157 | TB-500 |
|---|---|---|
| Molecular Formula | C₆₂H₉₈N₁₆O₂₂ | C₃₈H₆₈N₁₀O₁₄ |
| Molecular Weight | 1419.556 g/mol | 889.018 g/mol |
| CAS Number | 137525-51-0 | 885340-08-9 |
| Amino Acid Sequence | — | — |
| PubMed Citations | 30 referenced | 29 referenced |
Explore Full Research Profiles
BPC-157
Overview BPC-157 (Body Protection Compound-157, Bepecin, PL 14736) is a synthetic pentadecapeptide composed of 15 amino acids (GEPPPGKPADDAGLV), derived from a partial sequence of a larger Body Protection Compound protein naturally found in human gastric juice.[1][2] Originally isolated by Dr....
TB-500
Overview TB-500 (also known as Fequesetide) is a synthetic heptapeptide corresponding to the N-acetylated amino acid sequence 17–23 of the naturally occurring protein Thymosin Beta-4 (Tβ4). Its sequence is Ac-LKKTETQ.[1][2] The parent molecule, Thymosin Beta-4, is a ubiquitous 43-amino acid...
Frequently Asked Research Questions
How are BPC-157 and TB-500 mechanistically different?
+
Which compound is more associated with gastric-tract research?
+
Which compound is more associated with cardiac and corneal research?
+
Can BPC-157 and TB-500 be studied together?
+
What is the relationship between TB-500 and Thymosin β4?
+
Why is BPC-157 stable in gastric juice?
+
What sizes does Pure U.S. Peptides supply?
+
PubMed Citations Referenced
- [1]Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. PMID: 21548867
- [2]Hsieh MJ, et al. BPC 157 promotes endothelial cell tube formation and angiogenesis through the VEGFR2 pathway. PLoS One. 2017;12(8):e0181903. PMID: 28767746
- [3]Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-80. PMID: 21030672
- [4]Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PMID: 26935537
- [5]Goldstein AL, et al. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-9. PMID: 16099219
- [6]Sosne G, et al. Thymosin beta 4 and the eye: I, II. Ann N Y Acad Sci. 2010;1194:97-107. PMID: 20536456
- [7]Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84(4):663-9. PMID: 17320857
- [8]Crockford D. Development of thymosin beta4 for treatment of patients with ischemic heart disease. Ann N Y Acad Sci. 2007;1112:385-95. PMID: 17600293
- [9]Seiwerth S, et al. BPC 157 and standard angiogenic growth factors. Curr Pharm Des. 2018;24(18):1972-1989. PMID: 29879879
More Peptide Comparisons
For Research Use Only (RUO). This comparison is for educational and informational purposes only. All products are intended solely for in-vitro research and laboratory experimentation. Products have not been approved by the FDA for human or veterinary use. Pure U.S. Peptides does not condone or encourage the use of these products for anything other than strictly defined research applications.
Educational Scope. The mechanisms, pathways, and research applications discussed on this page describe published in-vitro, ex-vivo, and animal-model literature. They do not constitute medical advice, recommendations, or guidance for in-human use. Cited PubMed references describe preclinical research findings only. Researchers should consult their institutional review processes and original literature before designing any research study using these compounds.